Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.17
AVEO's Cash to Debt is ranked lower than
72% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. AVEO: 2.17 )
Ranked among companies with meaningful Cash to Debt only.
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: N/A
Current: 2.17

Equity to Asset 0.29
AVEO's Equity to Asset is ranked lower than
85% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AVEO: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.79
Current: 0.29

-3.21
0.79
F-Score: 1
Z-Score: -14.71
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1842.57
AVEO's Operating margin (%) is ranked lower than
82% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. AVEO: -1842.57 )
Ranked among companies with meaningful Operating margin (%) only.
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -1842.57

-8035.89
20.59
Net-margin (%) -1925.33
AVEO's Net-margin (%) is ranked lower than
84% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. AVEO: -1925.33 )
Ranked among companies with meaningful Net-margin (%) only.
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -1925.33

-8277.57
18.59
ROE (%) -158.18
AVEO's ROE (%) is ranked lower than
89% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. AVEO: -158.18 )
Ranked among companies with meaningful ROE (%) only.
AVEO' s 10-Year ROE (%) Range
Min: -116.49   Max: 20.76
Current: -158.18

-116.49
20.76
ROA (%) -65.11
AVEO's ROA (%) is ranked lower than
79% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. AVEO: -65.11 )
Ranked among companies with meaningful ROA (%) only.
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -65.11

-88.25
13.74
ROC (Joel Greenblatt) (%) -413.03
AVEO's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. AVEO: -413.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -413.03

-1669.78
678.74
Revenue Growth (3Y)(%) -55.50
AVEO's Revenue Growth (3Y)(%) is ranked lower than
85% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. AVEO: -55.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVEO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -55.5
Current: -55.5

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Paul Tudor Jones 106,701 sh (unchged)
Seth Klarman 3,829,350 sh (unchged)
» More
Q3 2014

AVEO Guru Trades in Q3 2014

Seth Klarman 3,829,350 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 99,319 sh (-6.92%)
Jim Simons 591,700 sh (-55.96%)
» More
Q4 2014

AVEO Guru Trades in Q4 2014

Jim Simons 675,800 sh (+14.21%)
Seth Klarman Sold Out
Seth Klarman Sold Out
Paul Tudor Jones 88,219 sh (-11.18%)
» More
Q1 2015

AVEO Guru Trades in Q1 2015

Jim Simons 1,276,000 sh (+88.81%)
Paul Tudor Jones 88,219 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.50
AVEO's P/B is ranked lower than
72% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AVEO: 7.50 )
Ranked among companies with meaningful P/B only.
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 7.5

0.87
22.16
P/S 36.10
AVEO's P/S is ranked lower than
75% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. AVEO: 36.10 )
Ranked among companies with meaningful P/S only.
AVEO' s 10-Year P/S Range
Min: 0.64   Max: 111.5
Current: 36.1

0.64
111.5
Current Ratio 1.67
AVEO's Current Ratio is ranked lower than
78% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. AVEO: 1.67 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s 10-Year Current Ratio Range
Min: 1.47   Max: 9.47
Current: 1.67

1.47
9.47
Quick Ratio 1.67
AVEO's Quick Ratio is ranked lower than
74% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. AVEO: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s 10-Year Quick Ratio Range
Min: 1.47   Max: 9.47
Current: 1.67

1.47
9.47
Days Sales Outstanding 116.42
AVEO's Days Sales Outstanding is ranked lower than
77% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. AVEO: 116.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s 10-Year Days Sales Outstanding Range
Min: 3.19   Max: 390.8
Current: 116.42

3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.60
AVEO's Price/Net Cash is ranked lower than
82% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: 14.50 vs. AVEO: 28.60 )
Ranked among companies with meaningful Price/Net Cash only.
AVEO' s 10-Year Price/Net Cash Range
Min: 1.75   Max: 24.76
Current: 28.6

1.75
24.76
Price/Net Current Asset Value 25.00
AVEO's Price/Net Current Asset Value is ranked lower than
80% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: 10.20 vs. AVEO: 25.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.42   Max: 19.54
Current: 25

1.42
19.54
Price/Tangible Book 7.40
AVEO's Price/Tangible Book is ranked higher than
52% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. AVEO: 7.40 )
Ranked among companies with meaningful Price/Tangible Book only.
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 7.4

1.2
14.66
Price/Median PS Value 7.40
AVEO's Price/Median PS Value is ranked higher than
56% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. AVEO: 7.40 )
Ranked among companies with meaningful Price/Median PS Value only.
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 23.13
Current: 7.4

0.16
23.13
Earnings Yield (Greenblatt) -58.30
AVEO's Earnings Yield (Greenblatt) is ranked lower than
93% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. AVEO: -58.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -59.3   Max: 48134.7
Current: -58.3

-59.3
48134.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
comment on AVEO Mar 15 2013 
comment on AVEO Mar 15 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO Oncology to Present at Jefferies 2015 Global Healthcare Conference May 29 2015
AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts May 26 2015
AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts May 26 2015
Can These Stocks Provide Investors with Further Gains? May 22 2015
BlackBerry, Monro Muffler, Valeant In Thursday's After-Hours Movers May 21 2015
How to Evaluate a 50% Move in AVEO May 21 2015
What's Up With The Delayed Reaction In Aveo Pharmaceuticals? May 21 2015
AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory... May 20 2015
AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory... May 20 2015
AVEO PHARMACEUTICALS INC Financials May 19 2015
On the move: New hires and appointments in the local life sciences industry May 11 2015
10-Q for AVEO Pharmaceuticals, Inc. May 10 2015
AVEO Pharmaceuticals' (AVEO) Q1 Loss Narrower than Expected - Tale of the Tape May 07 2015
AVEO Oncology Reports First Quarter 2015 Financial Results May 07 2015
AVEO PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 07 2015
Will AVEO Pharmaceuticals (AVEO) Surprise This Earnings? - Analyst Blog May 05 2015
Zacks Rank #1 Additions for Monday - Tale of the Tape May 04 2015
United Therapeutics Falls on Q1 Loss, Misses on Revenues - Analyst Blog Apr 29 2015
Hospira, Set to Be Acquired by Pfizer, Beats on Q1 Earnings - Analyst Blog Apr 28 2015
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog Apr 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK